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have been to determine an MR sequence capable of 
visualising the tumour and finding a suitable esophageal 
applicator that can be visualised on the MR images. 
 
Material and Methods: A total of six patients were included 
in this study. Each patient was scanned with one of two T2-
weighted sequences, inversion recovery fast spin echo (IR 
FSE) or fast recovery fast spin echo (FRFSE). To reduce the 
motion artefacts in the images, the scanning was only 
triggered when the diaphragm was at the end-exhale 
position. The imaging was performed on a 3.0 T MR (GE 
Healthcare). Dose planning on the obtained MR images was 
performed using two different methods 1) dose was 
prescribed at 10 mm from the applicator’s centre, which is 
the method currently used at Skåne University Hospital for 
treatment based on 2D images 2) dose planning was 
performed by manual optimisation, i.e. the dwell times were 
manually adjusted until adequate tumour coverage was 
reached. To our knowledge, an MR-safe esophageal 
applicator could not be found at the time of this study. 
Instead a modified duodenal tube was used. Different 
contrast agents were studied with the purpose to render the 
tube’s visibility on the MR images. 
 
Results: The esophageal tumour was successfully visualised 
and delineated on T2-weighted images with the FRFSE 
sequences, whereas the tumour in the MR images from the IR 
FSE sequences was difficult to visualise due to poor image 
quality. Furthermore, improved dose coverage to the tumour 
was observed when the dose planning was manually 
optimised to the tumour volume, where V100% to the tumour 
was increased from 70% to 95% and D90% was increased by 
34%. Moreover, the esophageal applicator (duodenal tube) 
was filled with a saline solution, which was successfully 
visualised on the MR images. 
 
Conclusion: Brachytherapy dose planning for esophageal 
cancer with MR imaging enhances tumour visibility and the 
ability to optimise the dose to the tumour volume and organs 
at risk. 
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Purpose or Objective; Papillon50 contact brachytherapy has 
been used for early rectal cancer treatment in the UK since 
1993. Currently there are four centres treating and a few 
more are in the process of implementation. The National 
Institute for Health and Care Excellence has issued guidance 
on safety and efficacy from a clinical perspective. However, 
there is currently no guidance on quality assurance (QA) 
testing. This review assessed any significant differences in 
machine QA practice between the current UK Papillon50 
users. This is the first step towards standardising QA tests, 
tolerances and procedures in order to ensure that the 
accuracy of this technique is maintained at a high level 
across the UK.  
 
Material and Methods: Each centre provided in-depth 
information regarding their QA programme. Details on 
machine-specific design characteristics were also taken into 
account. An inter-departmental comparison was made with 
regards to the QA tests performed, the frequency of each 
test, the accepted accuracy of the results with respect to the 
set baselines, the setup for each test and the equipment 
used.  
 
Results: Significant differences were seen between centres in 
the QA tests in terms of types of test, frequency and 
acceptable accuracy. A tolerance variation of 10% versus 2% 
in the beam quality check and a difference of 2 mm versus 
0.5 mm in the radiation field size check were observed. The 
manufacturer provides a calibration jig with which all four 
centres carry out radiation output measurements. However, 
each centre uses its own HVL jig design. There are significant 
design differences between these jigs with respect to the 
source-to-detector distance (SDD), the narrow beam 
geometry achieved and the backscatter conditions. All 
centres use the 1996 IPEMB CoP for the determination of 
absorbed dose for x-rays below 300 kV generating potential 
and its Addendum (2005) as a reference for the 
determination of the radiation output. However, the 
reference conditions stated in the CoP were generally not 
met due to the inherent design of the calibration jig used.  
 
Conclusion: Significant differences exist between centres in 
the level of accuracy and extent of the QA programme. The 
very-low energy and short SDD in the Papillon50 system result 
in a very rapid dose fall-off. Differences in the design of the 
HVL jig may play an important role in the definition of the 
beam quality in such conditions. An extension of the CoP 
Addendum may be needed to include the achievable 
Papillon50 measurement conditions. This review highlights 
the need to carry out an independent audit in order to assess 
whether the inter-departmental variations observed could 
result in differences in the treatment received by patients. 
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Purpose or Objective: To develop and assess the feasibility 
of an in-house developed fluorescent screen based system on 
dose distribution verification of HDR brachytherapy 
treatment delivery. 
 
Material and Methods: The QA system consisted of a solid 
water block with various thicknesses on top of a fluorescent 
screen (Kodak, Lanex regular screen) and a PMMA block 
below the screen. The fluorescent signal light was reflected 
by a mirror below the transparent PMMA to a CCD camera. 
The whole system was contained in a light tight box. Dose 
linearity was examined in a previous experiment. In 
measurement, an Ir-192 source was loaded to an applicator 
positioned on top of the solid water block. Single source dose 
distribution without entrance dose effect was first acquired 
to help obtain a universal light deconvolution kernel. It will 
then be used in subsequent image processing. Two source 
dwell positions were placed in each measurement with equal 
weighting. Source intervals were 5 mm and 10 mm. Four 
different measurement distances were selected, ranging from 
5 mm to 30 mm away from the applicator. Various dwell 
times ranging from 0.8s to 8s were assigned at different 
depth to produce the optimal light output. Captured images 
were then processed by applying a median-filter and the 
deconvolution kernel to remove radiation induced noise and 
deconvolute the acquired image, respectively. After the 
image processing, images were normalized and a region of 
interest (ROI) (16 cm²) was selected. Gamma index 
comparisons were performed between acquired dose 
distributions and the respective depth calculated by TPS 
(Elekta, Oncentra). Two profiles which cross the central line 
of the source dwell positions were obtained. 
 
Results: The system can obtain a dose distribution with 
resolution 0.257 mm per pixel. Gamma index comparisons, 
(3% dose difference/1 mm DTA) were performed on all 8 
conditions. Results were tabulated in Table 1. 
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All gamma indexes have passing rate above 95%. At 
measurement distances 10 mm to 30 mm, areas which failed 
to meet the gamma index criteria were, mostly, on the 
peripheral of the ROI. Gamma index near the source dwell 
position is well below 1. At measurement distance 5 mm 
away from source, the discrepancy between measurement 
and TPS calculation is the most severe. Both cases have 
points fail to meet the gamma criteria on the entrance path 
of the source. In particular, for 10 mm source separation, 
while assigning equal weighting for both dwell positions, 
measured data has two uneven signal peaks, as shown in Fig. 
1 (d)-(f). 
 
 
Conclusion: The system measured dose distributions agreed 
closely with TPS calculations, gamma index (3% dose 
difference/1 mm DTA) passing rates are all above 95% despite 
a high dose gradient near the source. Hence, this system can 
serve as a dose verification tool in afterloading 
brachytherapy. Besides, transit dose is detectable by this 
system but insignificant in a brachytherapy treatment. 
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Purpose or Objective: Due to the steep dose gradients close 
to a radiation source and the properties of the changing 
photon spectra, dose measurements in Brachytherapy usually 
have large uncertainties and are therefore scarcely 
performed in clinical routine. On the other hand, 
recommendations for experimental measurements are 
traditionally part of dosimetry protocols which in Germany 
are formulated in DIN standards. Within the revision of the 
outdated DIN standard for clinical brachytherapy dosimetry a 
working group (DIN 6803-3) was charged to formulate 
recommendations for brachytherapy dosimetry incorporating 
recent developments in brachytherapy in the description of 
radiation fields as well as new detectors and phantom 
materials. The Goal is to prepare methods and instruments 
e.g. to verify the emerging new dose calculation algorithms, 
for clinical dose verification and for in-vivo dosimetry.  
 
Material and Methods: After an analysis of the distance 
dependent spectral changes of the radiation field surrounding 
a brachytherapy source, the energy dependent response of a 
number of typical brachytherapy detectors was examined 
with Monte Carlo simulations. A dosimetric formalism was 
developed which allows the correction of the energy 
dependence as a function of the source distance for a Co-60 
calibrated detector. A number of phantom materials were 
examined with Monte Carlo calculations for their specific 
influence on the brachytherapy photon spectrum and on their 
water equivalence. 
 
Results: A simple description of the energy dependence of a 
detector in the vicinity of a brachytherapy source was found 
by defining an energy correction factor kQ for brachytherapy 
in the same manner as in existing dosimetry protocols. The 
factor can be calculated as a polynomial of the distance from 
the source. Volume averaging and radiation field distortion 
by the detector are incorporated into kQ. Materials for solid 
phantoms were identified which allow precise positioning of a 
detector close to a source together with small correctable 
deviations from absorbed dose to water. Recommendations 
for the selection of detectors and phantom materials are 
being developed for different measurements in 
brachytherapy. 
 
Conclusion: The introduction of an energy correction factor 
kQ for brachytherapy sources may allow more systematic and 
comparable dose measurements. In principle, the corrections 
can be verified or even determined by measurement in a 
water phantom and comparison with dose distributions 
calculated using the TG43 dosimetry formalism. 
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Purpose or Objective: Thirteen commercially available 
phantom materials have been tested by Monte Carlo 
simulations of a typical 192Ir therapy source with regard to 
their suitability as water substitutes in high energy 
brachytherapy. 
 
Material and Methods: The radial dose-to-water profiles in 
differently sized cylindrical water substitute phantoms 
surrounding a centric and coaxially arranged Varian 
GammaMed afterloading 192Ir brachytherapy source were 
compared to the corresponding dose-to-water profiles in 
equally sized water phantoms in order to evaluate the water 
equivalence of each phantom material within the clinically 
relevant source center distances up to 10 cm in the 
transversal plane. Monte Carlo simulations were performed in 
EGSnrc. The studied phantom materials are RW1, RW3 (both 
PTW, Germany), Plastic Water (as of 1995), Original Plastic 
Water (as of 2015), Plastic Water DT, Plastic Water LR (all 
CIRS, USA), Solid Water, HE Solid Water (both Gammex, USA), 
Virtual Water (Med-Cal, USA), Blue Water (Standard Imaging, 
USA), polyethylene, polystyrene and PMMA.  
Phantom sizes were varied between diameters and heights of 
10 cm and 60 cm to study the effect on the dose contribution 
by scattered photons. The radial variations of the total 
